

# GENEVA BIO FORUM

**Tuesday, October 2, 2007 at 12:00 – 14:30**

Centre de Conférences de Varembe (CCV), 9-11 Rue de Varembe, Geneva

## The Complexity of Biopharmaceuticals: Opportunities & Challenges of Biotech Medicines

### Speakers' Biography

#### ***PROF. HUUB SCHELLEKENS***

Dr. Huub Schellekens is professor of Medical Biotechnology and director of the Central Laboratory Animal Institute of Utrecht University in the Netherlands. He teaches Medical Biotechnology at the Department of Innovation Studies and has a research position at the Faculty of Pharmaceutical Sciences at the same university. He is a member of the Dutch Medicine Evaluation Board and National Expert of the European Medicine Evaluation Agency. He is a medical microbiologist by training and works on the preclinical development of biopharmaceuticals. He published more than 250 papers in peer reviewed international journals concerning many aspects of the development of therapeutic proteins. During the last years his work has included the immunogenicity of protein drugs.

Prior to joining Utrecht University, he was deputy director of the Dutch Primate Center, director of Mediscand Ingeny and medical microbiologist at the Reinier de Graaf Hospital in Delft the Netherlands. In 1992-1997 he coordinated an EU concerted action on the antigenicity of r-DNA derived pharmaceuticals.

He studied medicine at Erasmus University in Rotterdam, The Netherlands (1967-1973). There he also did his training in Medical Microbiology (1973-1980) and received his Ph.D. in 1980.

#### ***DR. KEN SEAMON***

Dr Ken Seamon is a Senior Associate at the Institute of Biotechnology, University of Cambridge. Dr Seamon was until recently Vice President, Regulatory Affairs at Amgen Corporation, with responsibility for the Regulatory CMC Group and interactions with operations, as well as for developing policy. Prior to this Dr Seamon was Senior Vice President, Drug Development at Immunex Corporation, Seattle, Washington State. Earlier in his career, Dr Seamon spent 13 years with the Food and Drug Administration (FDA), and served latterly as the Director of the Office of Therapeutics Research and Review and Associate Director for Research at the Center for Biologics Research and Review at Bethesda, Maryland. Dr. Seamon has been involved with regulation of biological products for over twenty years and has participated in a number of international initiatives for harmonizing the development and approval of biological and biotechnology products. Dr. Seamon has a Ph.D. in Chemistry from Carnegie Mellon University and his research background is in protein structure and function and molecular pharmacology.